Protective effect of pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitor on ischemia-induced neuronal damage

Neurological Research

Volumn 26, Issue 6, 2004, Pages 684-691

  Kurosaki, R ^a   Muramatsu, Y ^b   Kato, H ^c   Araki, T ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Gerbils; Hippocampus; Immunohistochemistry; Nitric oxide synthase; Transient forebrain ischemia

Indexed keywords

NITRIC OXIDE SYNTHASE; PITAVASTATIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CELL LOSS; COMMON CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; GERBIL; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; UPREGULATION;

ANIMALS; BRAIN ISCHEMIA; GERBILLINAE; HIPPOCAMPUS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; QUINOLINES;

EID: 12544257651     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164104225014102     Document Type: Article

References (37)

1. Pulsinelli WA, Brierley JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 1982; 11: 491-498
2. Zola-Morgan S, Squire LR, Amaral DG. Human amnesia and the medial temporal region: Enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 1986; 6: 2950-2967
3. Kirino T, Tamura A, Sano K. Selective vulnerability of the hippocampus to ischemia-reversible and irreversible types of ischemic cell damage. Prog Brain Res 1985; 63: 39-58
4. Araki T, Kato H, Kogure K. Selective neuronal vulnerability following transient cerebral ischemia in the gerbil: Distribution and time course. Acta Neurol Scand 1989; 80: 548-553
5. Araki T, Kato H, Inoue T, et al. Regional impairment of protein synthesis following brief cerebral ischemia in the gerbils. Acta Neropathol 1990; 79: 501-505
6. Dawson TM, Dawson VL. Nitric oxide: Actions and pathological roles. Neuroscientist 1995; 1: 7-18
7. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997; 20: 132-139
8. Yun HY, Dawson VL, Dawson TM. Nitric oxide in health and disease of the nervous system. Mol Psychiatry 1997; 2: 300-310
9. Choi DW. Nitric oxide: Foe or friend to the injured brain? Proc Natl Acad Sci USA 1993; 90: 9741-9743
10. Iadecola C, Pelligrino DA, Moskowitz MA, et al. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab 1994; 14: 175-192
11. Dawson VL, Dawson TW, London ED, et al. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991; 88: 6368-6371
12. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142
13. Dawson TM, Snyder SH. Cases as biological messengers: Nitric oxide and carbon monoxide in the brain. J Neurosci 1994; 14: 5147-5159
14. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 1990; 347: 768-770
15. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993; 268: 12331-12234
16. Bredt DS, Glatt CE, Hwang PM, et al. Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 1991; 7: 615-624
17. Huang PL, Dawson TM, Bredt DS, et al. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993; 75: 1273-1286
18. Lowenstein CJ, Glatt CS, Bredt DS, et al. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc Natl Acad Sci USA 1992; 89: 6711-6715
19. Simmons ML, Murphy S. Induction of nitric oxide synthase in glia cells. J Neurochem 1992; 59: 897-905
20. Iadecola C, Xu X, Zhang F, et al. Marked induction of calcium-independent nitric oxide synthase activity after focal cerebral ischemia. J Cereb Blood Flow Matab 1995; 15: 52-59
21. Dinerman JL, Dawson TM, Schell MJ, et al. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: Implications for synaptic plasticity. Proc Natl Acad Sci USA 1994; 91: 4214-4218
22. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-8885
23. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim Forsch/Drug Res 1997; 47: 904-909
24. Kojima J, Fujino H, Abe H, et al. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 1999; 22: 142-150
25. Kirino T, Tamura A, Sano K. A reversible type of neuronal injury following ischemia in the gerbil hippocampus. Stroke 1986; 17: 455-459
26. Araki T, Kumagai T, Tanaka K, et al. Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res 2001; 918: 176-181
27. Kurosaki R, Muramatsu Y, Michimata M, et al. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Neurol Res 2002; 24: 655-662
28. Kato H, Kogure K, Araki T, et al. Immunohistochemical localization of superoxide dismutase in the hippocampus following ischemia in a gerbil model of ischemic tolerance. J Cereb Blood Flow Metab 1995; 15: 60-70
29. 4). J Histochem Cytochem 1990; 38: 1683-1686
30. Fujino H, Kojima J, Yamada Y, et al. Studies on the metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans. Xenobiot Metab Dispos 1999; 14: 79-91
31. Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am J Cardiol 2000; 85: 178-183
32. Suzuki H, Aoki T, Tamaki T, et al. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 1999; 146: 259-270
33. Noji Y, Higashikata T, Inazu A, et al. for the Hokuriku NK-104 Study Group. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002; 163: 157-164
34. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-31729
35. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211-216
36. Laufs U, Fata VL, Plutzky J, et al. Upregulation of endothelial oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135
37. Kaesemeyer WH, Caldwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-241